Lacrimal Apparatus Disease Clinical Trial
Official title:
Lacrimal Drainage System Obstruction Associated to Radioactive Iodine Therapy for Thyroid Carcinoma
The radioactive radioiodine therapy (Na131I) for the treatment of differentiated thyroid
carcinoma is a procedure used for ablation of remaining thyroid tissue after thyroidectomy
and metastases. Although serious complications are uncommon after treatment, there are
well-documented adverse reactions secondary to the involvement of the salivary glands, such
as dry mouth, pain in the parotid glands and dysphagia, even after administration of low
doses of radioiodine. However, ocular complications of such treatment are scarcely reported
in literature.
Among them the investigators can mention recurrent and chronic conjunctivitis,
keratoconjunctivitis sicca and dry eye, affecting 23% of patients undergoing radioactive
iodine therapy. Dysfunction of the lacrimal gland is described in recent studies, especially
after high cumulative dose of the drug. Likewise, epiphora and nasolacrimal duct obstruction
have been reported as complications associated with the use of radioiodine, although studies
are not available to assess its true incidence through the systematic evaluation of
patients.
It can be seen in routine practice that these patients would normally be referred for
ophthalmological examination only if a complaint, what happens in the process of OVL already
installed after the use of high doses of radioiodine. With the early evaluation of these
patients, the investigators focused on detecting the process of ongoing obstruction in order
to study interventions that prevent its final installation.
n/a
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00001598 -
DHEA Treatment for Sjogren's Syndrome
|
Phase 2 |